Evidence map›Paper›PMID 36818674›Full record

ArticleFrontiers in oncology2022

A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy.

Daryl Lim Joon, Colleen Berry, Benjamin Harris, Mark Tacey, Drew Smith, Nathan Lawrentschuk, Michal Elisabeth Schneider, Olivia Fraser, Megan Hall, Michael Chao and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Universal Fiducial Markers for Multi-Modal Radiotherapy.International journal of particle therapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daryl Lim JoonRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Colleen BerryRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Benjamin HarrisRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Mark TaceyOffice of Research, The Northern Hospital, Epping, VIC, Australia.
Drew SmithRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Nathan LawrentschukAustin Health, University of Melbourne, Melbourne, VIC, Australia.
Michal Elisabeth SchneiderDepartment of Medical Imaging and Radiation Sciences, Monash University, Melbourne, VIC, Australia.
Olivia FraserRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Megan HallRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Michael ChaoRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Farshad ForoudiRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Trish JenkinsRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
David AngusRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Morikatsu WadaRadiation Oncology Department, Olivia Newton-John Cancer Centre, Heidelberg, VIC, Australia.
Shomik SenguptaAustin Health, University of Melbourne, Melbourne, VIC, Australia.
Vincent KhooDepartment of Clinical Oncology, Royal Marsden Hospital, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. Methods: Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. Results: Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. Conclusions: Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification.

Indexed as

image guided radiotherapypolymer fiducialsprostate cancerradiotherapyverification

Identifiers

PMID36818674
PMCPMC9930895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.